Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

High-risk human papillomavirus DNA in the primary tumor, sentinel, and nonsentinel pelvic lymph nodes in patients with early-stage cervical cancer: a correlation with histopathology

J. Sláma, M. Dražďáková, P. Dundr, D. Fischerová, M. Zikán, I. Pinkavová, P. Freitag, D. Pavlišta, T. Zima, D. Cibula

. 2009 ; 19 (4) : 703-707.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11019634

Grantová podpora
NS10037 MZ0 CEP - Centrální evidence projektů

INTRODUCTION: Metastatic involvement of pelvic lymph nodes is the most important prognostic parameter in early-stage cervical cancer. Still, approximately 15% of patients with negative pelvic nodes experience recurrence, most of them in the pelvis. The presence of human papillomavirus (HPV) DNA in histologically negative pelvic nodes is considered a subclinical metastatic spread. METHODS: Patients with early-stage cervical cancer referred for surgical treatment were enrolled in the study. Cytobrush technique was used for sample collection from the fresh tissue to avoid any loss of material for histology. RESULTS: Altogether, 49 patients were enrolled in the study. High-risk (HR) HPV DNA was identified in the tumor in 91.8% patients and in the sentinel node or other pelvic nodes in 49.9% patients. Among the 10 HR HPV genotypes detected, HPV 16 was the most frequently represented in both the tumor and the lymph nodes (66.7% and 71.4%, respectively). All metastatic lymph nodes were HR HPV positive. CONCLUSIONS: The presence of HR HPV DNA in a sentinel node had a 100% positive predictive value for metastatic involvement of pelvic lymph nodes in our study. This could be considered a sign of an early subclinical metastatic spread; however, the prognostic value has to be evaluated through a longer follow-up.

Citace poskytuje Crossref.org

000      
03668naa 2200565 a 4500
001      
bmc11019634
003      
CZ-PrNML
005      
20140328105749.0
008      
110714s2009 xxu e eng||
009      
AR
024    __
$a 10.1111/igc.0b013e3181a13186 $2 doi
035    __
$a (PubMed)19509575
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sláma, Jiří $7 xx0105772
245    10
$a High-risk human papillomavirus DNA in the primary tumor, sentinel, and nonsentinel pelvic lymph nodes in patients with early-stage cervical cancer: a correlation with histopathology / $c J. Sláma, M. Dražďáková, P. Dundr, D. Fischerová, M. Zikán, I. Pinkavová, P. Freitag, D. Pavlišta, T. Zima, D. Cibula
314    __
$a General Teaching Hospital, Department of Oncogynecology, 1st Medical School of Charles University, Prague 2, Czech Republic. slamajiri@centrum.cz
520    9_
$a INTRODUCTION: Metastatic involvement of pelvic lymph nodes is the most important prognostic parameter in early-stage cervical cancer. Still, approximately 15% of patients with negative pelvic nodes experience recurrence, most of them in the pelvis. The presence of human papillomavirus (HPV) DNA in histologically negative pelvic nodes is considered a subclinical metastatic spread. METHODS: Patients with early-stage cervical cancer referred for surgical treatment were enrolled in the study. Cytobrush technique was used for sample collection from the fresh tissue to avoid any loss of material for histology. RESULTS: Altogether, 49 patients were enrolled in the study. High-risk (HR) HPV DNA was identified in the tumor in 91.8% patients and in the sentinel node or other pelvic nodes in 49.9% patients. Among the 10 HR HPV genotypes detected, HPV 16 was the most frequently represented in both the tumor and the lymph nodes (66.7% and 71.4%, respectively). All metastatic lymph nodes were HR HPV positive. CONCLUSIONS: The presence of HR HPV DNA in a sentinel node had a 100% positive predictive value for metastatic involvement of pelvic lymph nodes in our study. This could be considered a sign of an early subclinical metastatic spread; however, the prognostic value has to be evaluated through a longer follow-up.
590    __
$a bohemika - dle Pubmed
650    _2
$a dospělí $7 D000328
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a cisplatina $x aplikace a dávkování $7 D002945
650    _2
$a DNA virů $x izolace a purifikace $7 D004279
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a ifosfamid $x aplikace a dávkování $7 D007069
650    _2
$a lymfatické uzliny $x patologie $x virologie $7 D008198
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a Papillomaviridae $x genetika $7 D027383
650    _2
$a infekce papilomavirem $x patologie $x virologie $7 D030361
650    _2
$a prospektivní studie $7 D011446
650    _2
$a biopsie sentinelové lymfatické uzliny $7 D021701
650    _2
$a nádory děložního čípku $x farmakoterapie $x chirurgie $x patologie $x virologie $7 D002583
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dražďáková, Marcela $7 xx0075797
700    1_
$a Dundr, Pavel $7 xx0080436
700    1_
$a Fischerová, Daniela $7 xx0074804
700    1_
$a Zikán, Michal, $d 1976- $7 xx0096708
700    1_
$a Pinkavová, Ivana, $7 xx0103207 $d 1976-
700    1_
$a Freitag, Pavel, $d 1951- $7 xx0018148
700    1_
$a Pavlišta, David $7 xx0057882
700    1_
$a Zima, Tomáš, $d 1966- $7 jn20000620440
700    1_
$a Cibula, David, $d 1968- $7 jo20000074072
773    0_
$t International Journal of Gynecological Cancer $w MED00009896 $g Roč. 19, č. 4 (2009), s. 703-707
910    __
$a ABA008 $b x $y 2 $z 0
990    __
$a 20110715114818 $b ABA008
991    __
$a 20140328105825 $b ABA008
999    __
$a ok $b bmc $g 864489 $s 729512
BAS    __
$a 3
BMC    __
$a 2009 $x MED00009896 $b 19 $c 4 $d 703-707 $m International journal of gynecological cancer $n Int J Gynecol Cancer
GRA    __
$a NS10037 $p MZ0
LZP    __
$a 2011-3B09/Bjvme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé